...
首页> 外文期刊>Transplantation Proceedings >Encapsulating Peritoneal Sclerosis in Peritoneal Dialysis Patients After Kidney Transplantation
【24h】

Encapsulating Peritoneal Sclerosis in Peritoneal Dialysis Patients After Kidney Transplantation

机译:肾移植后腹膜透析患者腹膜硬化术

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Abstract Objective Encapsulating peritoneal sclerosis (EPS) is a serious complication for patients with chronic kidney disease (CKD) who were treated with long-term peritoneal dialysis (PD). The risk of EPS was increased after kidney transplantation. In our study we evaluated risk factors for EPS patients after kidney transplantation who were treated before with PD. Materials and Methods In our study, between January 2008 and August 2015, 47 PD patients (12 had EPS) who underwent kidney transplantation were analyzed. Age, gender, time of PD treatment, human leukocyte antigen (HLA) matching, cold ischemia time, kidney function (serum urea, creatinine, etc), comorbidities, immunosuppressive therapy, clinical features, and outcomes of PD patients were retrospectively evaluated in both groups. Results Mean age was 42 (range, 25–60) years in EPS patients, versus 43 (range, 22–77) years without EPS ( P ?= .798). Distribution of gender was similar in both groups ( P ?= .154). The C-reactive protein levels ( P ? P ?= .001), length of time on PD ( P ? P ?= .020) were higher in EPS patients. The immunosuppressive therapy was changed; tamoxifen and steroids were used after diagnosis in EPS patients. HLA matching was higher in the non-EPS group ( P ?=?.006). EPS was more often seen in patients who were treated with continuous ambulatory peritoneal dialysis (CAPD; 75%; P ?= .036). EPS was more often detected in cadaveric transplant recipients (83.3%; P ?= .024). High peritoneal transmittance rate was more identified in EPS (+) patients ( P ?= .001). EPS was more often seen in patients who were treated with icodextrin-based regimens in PD before transplantation (91.7%; P ?= .037). The length of time on PD and high ferritin levels increased EPS 1.08 and 1.01, respectively ( P ?= .036 and .049, respectively), in multivariate analysis. Conclusion The length of time on PD, type of PD, PD regimens with icodextrin, episodes of peritonitis, and peritoneal transmittance in patients with CKD affect the development of EPS after transplantation.
机译:摘要腹膜硬化(EPS)对慢性肾疾病(CKD)的患者进行了严重并发症,他是长期腹膜透析(PD)治疗的。肾移植后EPS的风险增加。在我们的研究中,我们在肾移植后评估了EPS患者的危险因素,患有PD治疗的肾移植。我们研究中的材料和方法,2008年1月至2015年8月期间,分析了47例接受肾移植的患者(12例EPS)。在两者中回顾性评估PD治疗(HLA)匹配,人白细胞抗原(HLA)匹配,冷缺血时间,肾功能(血清尿素,患者,临床特征,患有PD患者的临床特征和结果团体。结果平均年龄为42(范围,25-60)岁,与43(范围,22-77)年没有EPS(P?= .798)。两组的性别分布相似(P?= .154)。 C-反应蛋白水平(P?P?= .001),在EPS患者中pd(p?p≤020)的时间长度较高。免疫抑制治疗改变;在EPS患者诊断后使用Tamoxifen和类固醇。非EPS组的HLA匹配更高(P?= 006)。用连续的动态腹膜透析治疗(CAPD; 75%; p?= .036)治疗的患者更常见于患者。在尸体移植受者中更常被检测到EP(83.3%; p?= .024)。在EPS(+)患者中更鉴定出高腹膜透射率(P?= .001)。在移植前用基于Icodextrin的方案治疗的患者更常见的EPS患者(91.7%; p?= .037)。 Pd和高铁蛋白水平上的时间长度分别增加了EPS 1.08和1.01(分别为P?= .036和.049),在多变量分析中。结论CKD患者PD,PD,腹膜炎,腹膜炎发作,腹膜炎发作和腹膜炎的腹膜炎的时间长度影响移植后EPS的发育。

著录项

  • 来源
    《Transplantation Proceedings》 |2018年第1期|共5页
  • 作者单位

    Uludag University Faculty of Medicine Department of Internal Medicine Division of Nephrology;

    Uludag University Faculty of Medicine Department of Internal Medicine Division of Nephrology;

    Uludag University Faculty of Medicine Department of Bioistatistics;

    Uludag University Faculty of Medicine Department of Internal Medicine;

    Uludag University Faculty of Medicine Department of Internal Medicine;

    Uludag University Faculty of Medicine Department of Internal Medicine Division of Nephrology;

    Uludag University Faculty of Medicine Department of Internal Medicine Division of Nephrology;

    Uludag University Faculty of Medicine Department of Internal Medicine Division of Nephrology;

    Uludag University Faculty of Medicine Department of Internal Medicine Division of Nephrology;

    Uludag University Faculty of Medicine Department of Internal Medicine Division of Nephrology;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 器官移植术;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号